FDA Approved: KISQALI — Original Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved Kisqali (ribociclib) in its original application (NDA 209092) from Novartis Pharmaceuticals Corporation for a breast cancer indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

ORIG AP for KISQALI (RIBOCICLIB)